Orgenesis Inc. Minority Interests

Minority Interests of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Minority Interests growth rates and interactive chart.


Highlights and Quick Summary

  • Minority Interests for the quarter ending December 30, 2019 was $31 Million (a 28.24% increase compared to previous quarter)
  • Year-over-year quarterly Minority Interests increased by 27.74%
  • Annual Minority Interests for 2019 was $31 Million (a 27.79% increase from previous year)
  • Annual Minority Interests for 2018 was $24.2 Million (a 0.29% increase from previous year)
  • Annual Minority Interests for 2018 was $24.2 Million (a 569.8% increase from previous year)
Visit stockrow.com/ORGS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Minority Interests of Orgenesis Inc.

Most recent Minority Interestsof ORGS including historical data for past 10 years.

Interactive Chart of Minority Interests of Orgenesis Inc.

Orgenesis Inc. Minority Interests for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $30.96 $24.14 $24.31 $24.23 $30.96
2018 $24.15 $18.65 $6.12 $3.88 $24.22
2017 $3.61 $3.61
2016 $0.0 $0.0 $0.0
2015 $0.0
2014 $0.0
2013 $0.0
2012 $0.0 $0.0

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.